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Abstract
Background: Hemophilia is an inherited bleeding disorder caused by a deficiency in a specific clotting factor. This results in
spontaneous bleeding episodes and eventual arthropathy. The mainstay of hemophilia treatment is prophylactic replacement of
the missing factor, but an optimal regimen remains to be determined. Rather, individualized prophylaxis has been suggested to
improve both patient safety and resource utilization. However, uptake of this approach has been hampered by the demanding
sampling schedules and complex calculations required to obtain individual estimates of pharmacokinetic (PK) parameters. The
use of population pharmacokinetics (PopPK) can alleviate this burden by reducing the number of plasma samples required for
accurate estimation, but few tools incorporating this approach are readily available to clinicians.
Objective: The Web-accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo) project aims to bridge this
gap by providing a Web-accessible service for the reliable estimation of individual PK parameters from only a few patient samples.
This service is predicated on the development of validated brand-specific PopPK models.
Methods: We describe the data analysis plan for the development and evaluation of each PopPK model to be incorporated into
the WAPPS-Hemo platform. The data sources and structure of the dataset are discussed first, followed by the procedures for
handling both data below limit of quantification (BLQ) and absence of such BLQ data. Next, we outline the strategies for building
the appropriate structural and covariate models, including the possible need for a process algorithm when PK behavior varies
between subjects or significant covariates are not provided. Prior to use in a prospective manner, the models will undergo extensive
evaluation using a variety of techniques such as diagnostic plots, bootstrap analysis and cross-validation. Finally, we describe
the incorporation of a validated PopPK model into the Bayesian post hoc model to produce individualized estimates of PK
parameters.
Results: Dense PK data has been collected for more than 20 brands of factor concentrate from both industry-sponsored and
investigator-driven studies. The model development process is underway for the majority of molecules, with refinement and
validation to be completed in 2017. Further, the WAPPS-Hemo co-investigator network has contributed more than 300 PK
assessments for use in model development and evaluation. This constitutes the largest repository of this type of PK data globally.
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Conclusions: The WAPPS-Hemo service aims to eliminate barriers to the uptake of individualized PK-tailored hemophilia
treatment. By incorporating this tool into routine practice, clinicians can implement a personalized dosing strategy without
performing rigorous sampling or complex calculations. This service is centred on validated models developed according to the
robust approach to PopPK modeling described herein.
ClinicalTrial: ClinicalTrials.gov NCT02061072; https://clinicaltrials.gov/ct2/show/NCT02061072 (Archived by WebCite at
http://www.webcitation.org/6mRIXJh55)
(JMIR Res Protoc 2016;5(4):e232)   doi:10.2196/resprot.6559
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Introduction
Background
Hemophilia is an inherited bleeding disorder caused by a
deficiency in clotting factor VIII (FVIII, hemophilia A) or factor
IX (FIX, hemophilia B). FVIII and FIX are key constituents in
the coagulation cascade, which produces fibrin clots in response
to blood vessel injury [1]. Consequently, hemophiliacs suffer
from spontaneous, often recurring, joint bleeds, eventually
leading to arthropathy. Hemophilia A is the more common form
of the disease, affecting approximately 1 in 5000 males, while
hemophilia B is considerably more rare (approximately 1 in
20,000) [2].
Modern hemophilia treatment consists of replacement of the
deficient factor [3]. Replacement therapy began with the
introduction of plasma-derived clotting factor concentrates in
the 1960s, and advances in DNA technologies in the 1990s
propelled the development of recombinant coagulation factors
and the more recent design of longer-lasting recombinant
products [4,5]. Clotting factor replacement therapy may be
administered according to two main treatment strategies:
episodic and prophylactic. The concept of prophylaxis, initiated
by Nilsson and colleagues in the 1970s [6,7], is derived from
the clinical observation that patients with moderate hemophilia
(ie, those with clotting factor activity greater than 1% of normal)
are less prone to the spontaneous bleeds and consequent
arthropathy seen in those with severe hemophilia [8]. Today,
there is global unanimity that prophylaxis should be initiated
in young children before joint disease is apparent [9-11], as
episodic treatment has been shown to be ineffective for the
prevention of arthropathy [10]. However, implementation of
the prophylactic approach varies considerably between countries
[12]. The cost and availability of factor concentrates are major
barriers to its widespread adoption, as is the challenge of patient
compliance [13].
Despite its proven clinical benefit, an optimal dosing strategy
for prophylaxis has yet to be determined. Evidence suggests
that treatment should be individualized for best results, both
from a therapeutic and economic perspective [14]. Typically,
the pharmacokinetic (PK) properties of factor concentrates are
assessed with classical PK studies, which are carried out in a
small homogeneous group of participants, usually young and
healthy. Subsequently, patients are empirically dosed by weight
based on average PK estimates without taking into account
individual variation in PK parameters beyond what can be
predicted by age and weight [15]. Indeed, participants who
appear similar may exhibit different PK behavior due to
unpredictable variability. For example, Collins et al examined
the variability in time to reach a critical factor level and found
significant variation not only between children and adults, but
within each group as well [16]. Unfortunately, performing an
individual PK study with a classical approach requires 11
samples – 4 in the distribution phase (0 to 1 h) and 7 in the
elimination phase (up to 48 h for FVIII, 72 h for FIX) – as
outlined in recommendations from the International Society on
Thrombosis and Haemostasis [17], making individualized
PK-tailored dosing a difficult approach to apply in a clinical
setting, especially when it involves pediatric patients.
One opportunity to overcome some of the limitations and
barriers discussed above is offered by population
pharmacokinetic (PopPK) modeling. Indeed, PopPK studies
can make use of both rich and sparse sampling, which allows
for a larger and more heterogeneous group of participants (eg,
pediatric, elderly, and critical care patients) to be included due
to less demanding sampling schedules [18]. Moreover, the
PopPK approach allows for the partitioning of the total
variability in PK response in a population into predictable and
unpredictable variability. Predictable variability can be attributed
to covariates that influence PK, such as body weight, age, and
disease phenotype, and the identification of meaningful
covariates can help to recognize at-risk subpopulations [19].
Unpredictable variability may occur both between subjects
(BSV) and within a single subject (WSV), and a main goal of
PopPK is to estimate the magnitude of these unexplained sources
of variability so that a suitable dosing strategy may be
determined [20,21]. In the case of hemophilia, WSV is small
relative to BSV [15], so an individualized dosing regimen is
appropriate. This approach is used in the therapeutic monitoring
of several other conditions [22-24], and a 2010 study by
Björkman et al indicated that a PopPK model combined with a
limited sampling strategy could be as useful for the prediction
of individual FVIII PK as a classical study [25]. However,
adoption of this method has been hampered due to the
complexity of the models needed to describe clotting factor PK
and a relative shortage of PK data due to the rarity of the disease.
In response, the Web-Accessible Population Pharmacokinetic
Service - Hemophilia (WAPPS-Hemo, NCT02061072) project
was launched in April 2013 at McMaster University, Hamilton,
Ontario, Canada. A detailed description of the project
methodology, objectives and progress is published separately
[26]. In brief, WAPPS-Hemo aims at supporting clinicians in
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assessing individual PK for more informed dosing decisions
(Textbox 1). The goal of the WAPPS-Hemo project is to set up
a centralized, dedicated, Web-accessible, actively moderated
service, allowing for (1) the input of anonymized and certified
patient data by clinicians; (2) automatic estimation of
patient-specific PK parameters; (3) expert validation of the
estimation process; and (4) reporting of estimates to clinicians
(Figure 1). WAPPS-Hemo represents the first non-industry
sponsored, Web-based PopPK Bayesian calculator providing
individualized PK estimates.
This report outlines the methods used for the development of
brand-specific PopPK models, which form the knowledge base
of the WAPPS-Hemo Bayesian individual forecast platform.
Textbox 1. The Web-Accessible Population Pharmacokinetic Service - Hemophilia project summary.
In the framework of the population pharmacokinetic (PopPK) approach, estimating reliable outcomes by the Web-Accessible Population Pharmacokinetic
Service - Hemophilia (WAPPS-Hemo) service requires that underlying PopPK models are well developed using a sufficiently large population of
individuals. The WAPPS-Hemo project has assembled a vast database of clotting factors VIII and IX pharmacokinetic (PK) data across numerous
brands and this represents the largest repository of this type of data globally. The repository includes PK data from industry sponsors and independent
investigators; furthermore, clinical sites contributing data to the WAPPS-Hemo repository for individual estimation agreed upon subsequent use of
those data for modeling. Indeed, onboarding of clinical sites requires that each participating site enters the network by signing a data transfer agreement
where the site commits to data provision and takes responsibility for clinical use of the results. The principal investigator of WAPPS-Hemo, Dr Alfonso
Iorio, agrees to share ownership of the database and authorship on any publication stemming from the project. Clinicians contribute to the repository
by submitting to the website as few as 3 to 4 factor levels per patient along with demographic information. The appropriate PopPK control file is
selected for the brand of factor concentrate identified in the patient data file. The online PopPK engine automatically estimates the relevant individual
PK parameters. Following expert validation, a patient report is generated and sent to the clinician that includes the time when the factor level reaches
a specified value, for example 0.05, 0.02 or 0.01 international units (IU) per mL, along with credibility intervals.
Figure 1. The Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo) platform uses brand-specific population
pharmacokinetic models and submitted patient data to generate reports of individual pharmacokinetic profiles and estimates.
Objectives
The primary objective of this report is to outline the methods
for developing PopPK models on dense FVIII and FIX data
obtained from the Data Sources to better understand the
relationship between blood plasma concentration and time for
each molecule investigated. PopPK model estimates will be
entered as priors in subsequent Bayesian post hoc analyses to
predict the most reliable function between blood plasma
concentration and time for patients with sparse data. This
function will be used to inform clinicians when the next dose
of a particular FVIII or FIX molecule should be administered.
Methods
Data Sources
Dense individual PK data on 878 participants using 21 different
molecules from 17 different sources have been collected as part
of industry-sponsored or investigator-driven studies. Most of
the data in the derivation cohort are provided as both clotting
and chromogenic assay results, but we plan to model exclusively
with data from clotting assays, as the data received from
participating clinical sites is almost uniquely of this type.
Characteristics of some of the dense data that has been obtained
for the WAPPS-Hemo project are summarized in Table 1. All
datasets reported the age and weight of the participants; certain
studies also reported additional covariates such as hematocrit,
von Willebrand factor levels, and blood type, which can be
tested during covariate analysis. In addition, individual patient
data is being collected continuously through the WAPPS-Hemo
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co-investigator network that currently has 47 active hemophilia
treatment centers registered. To date, close to 300 profiles have
been submitted.













aN: number of participants.
bvWF: von Willebrand factor.
cFVIII: clotting factor FVIII.
dFIX: clotting factor FIX.
Dataset Assembly
Rich Dataset
Rich data used for PopPK modeling are provided by the data
sources. These data will be received in various software
packages and in a variety of formats, so they will be re-formatted
into a standard comma-separated values (CSV) file for input
into the PopPK modeling software, NONMEM (v 7.3.0; ICON
Development Systems, Ellicott City, MD, US). Where possible,
the dataset will consist of the variables shown in Table 2. AMT,
DV, TIMEH, AGE, and BW are required to be provided by the
data source. The optional covariates (HT, VWF, RACE, BTYPE,
and HCT) are collected if possible.
Structure of the NONMEM Dataset
The record for each patient is organized as follows. The first
record is used to read in the pre-dose amount, which accounts
for the patient’s endogenous factor level and any residual factor
from a previous dose, if measured. The TIMEH entry for the
first record is set to zero, and this is the reference point for the
time for all subsequent records in the dataset. The first record
also contains the BASELINE value, which corresponds to the
patient’s endogenous factor level. If a baseline level of the factor
was measured, the measured value is entered; if not, a baseline
value of 0.005 IU/mL (0.5% of normal factor activity) is
assumed.
The second record is used to read in the dose administered
(AMT). For this entry, the TIMEH column contains the time
(in hours) that was required to administer the dose (eg, 0.1666
for a 10-minute administration). The amount and time are used
to calculate the rate (RATE=AMT/TIMEH). For all subsequent
records, AMT and RATE are set equal to zero.
The third record contains the first valid observation of the
plasma concentration and subsequent records contain subsequent
valid observations of the plasma concentration. The one
exception to this is records following a valid observation that
refer to samples that are below the limit of quantification (BLQ).
Because the information from these different events (eg,
PREDOSE, BASELINE, concentration observations, and BLQ
events) needs to be handled in different ways, indicator variables
MDV3 and MDV5 are included to designate how each entry
should be used.
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Table 2. Typical variables in NONMEM datasets.
UnitsDescriptionVariable
Required variables
Positive integerPatient identification numberCID
Positive integerDose occasionOCC
Hours or fraction of hours (minimum of 4 decimal places)Time for each concentration measurement from start of bolusTIMEH
IUaTotal doseAMT
IU/hRate of entry of drug: AMT/TIMEHRATE
IU/LPlasma concentration of valid observation or BLQbDV
Positive integer, yearsAgeAGE
Positive integer, kilogramsWeightBW
Positive integer (0=valid observation, 1= dose, 3=BLQ observation)Event identification variableEVID
Positive number, IU/kgAMT/BWDOSE
Zero or positive integer if measured, –1 if not measured (IU/L)Plasma concentration at time of start of bolusPREDOSE
0=valid observation; 1=dose or BLQ observation; MDV5=MDV
when no BLQ
Missing dependent variableMDV5
Positive integer if known, –1 if not known, IU/LEndogenous plasma concentrationBASELINE
≤ 0=non BLQ measurement, positive integer=BLQ value, IU/LBelow limit of quantificationBLQ






Positive integer (1=White, 2=Black, 3=…)RaceRACE
Positive integer (1=A, 2=B, 3=AB, 4=O)Blood typeBTYPE
PercentageHematocritHCT
aIU: international unit.
bBLQ: below the limit of quantification.
Data Checking
Errors and Missing Data
Prior to analyzing the data, the integrity of the data will be
scrutinized to identify potential data errors. Errors can exist for
a number of reasons. For example, following a dose, plasma
concentrations typically decline with time so if a plasma
concentration for a record is higher than the plasma
concentration for a previous record, that record will be flagged
to be checked. If any data are missing they will be flagged to
be checked. Similarly, outlying covariate values for continuous
variables (eg, AGE, BW, or HT) will be flagged to be checked.
Any categorical variable that has a value that is not expected
will be flagged to be checked. Duplicate records within a
patient’s data will also be flagged.
Procedures for Handling Data Errors
All potentially erroneous data will be reported and discussed.
If a resolution to the error is forthcoming, it will be documented
and the appropriate changes will be made to the dataset. If no
resolution is found, the error will be documented and the data
will be excluded from subsequent analyses.
Data Modeling Methods
Software, Subroutines, and the Handling of Data Below
the Limit of Quantification
Nonlinear mixed effects modeling and Bayesian post hoc
estimations will be completed in NONMEM and PDx-Pop (v
5.10; ICON Development Systems, Ellicott City, MD, US).
PopPK modeling will be performed using the first order
conditional estimation with interaction (FOCEI) method. The
ADVAN and TRANS subroutines for each model, which specify
the model structure and parameterization, respectively, are
shown in Table 3.
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Table 3. NONMEM subroutines used to implement kinetic equations for linear models following intravenous administration.
TRANS subroutineADVAN subroutineModel
TRANS2: CL, VADVAN11-compartment
TRANS4: CL, V1, Q, V2ADVAN32-compartment
TRANS4: CL, V1, Q2, V2, Q3, V3ADVAN113-compartment
Severe hemophilia patients have, by definition, an endogenous
coagulation factor level below 0.01 IU/mL, which is also often
cited as the limit of quantification (LOQ) for coagulation activity
assays [27-29]. As a result, trough concentrations are often BLQ
and several methods exist for the handling of samples that are
BLQ. Simpler methods exclude BLQ data or replace these points
with LOQ/2; this protocol makes use of the M3 method
described by Beal in 2001 [30].
Structural Model Building
The first step in model development will be a naïve pooled
analysis, which allows for preliminary exploration of model
structure and mean estimates of PK parameters. Further
definition of the model structure (ie, number of compartments)
will be determined using a combination of graphical techniques
and numerical goodness-of-fit measures. Models will be
evaluated using an objective function value based on a
summation of the residual error. One model is considered to be
superior to a similar hierarchically well-formulated model with
one more degrees of freedom if the objective function decreases
by 3.84 units or more, based on the assumption of a chi squared
(χ2) distribution. Models will also be evaluated using diagnostic
plots (Textbox 2).
Textbox 2. Diagnostic plots used to evaluate the models.
• Observed values vs individual/population predicted values
• Conditional weight residuals (CWRES) vs predicted values
• CWRES vs time




• Population covariate plots
In the event that it is difficult to determine which structure best
characterizes the data, it may be helpful to fit each subject
individually to explore the reasons for unexplained variability.
For example, some factor concentrates may exhibit different
structures between patients, which may in turn require estimates
to be derived from both models followed by a comparison of
the effects on population estimates and individual dosing
decisions; as a rule of thumb, we will always take the most
conservative approach.
The goal of PopPK is to describe the concentration-time profile
for each subject using a series of mathematical equations in a
hierarchical manner (Figure 2). Observed concentrations are
expressed as a function of an individual’s PK parameters (θ)
and time (t), with a residual error term (ε) to account for
unexplained variability within the individual (Figure 3, Equation
1).
The appropriate structure for the residual unexplained variability
(RUV, ε) will be determined using graphical goodness-of-fit
plots (including histograms of the residuals, normal QQ plots,
and plots of the residuals vs predicted values) and numerical
measures (such as objective function value and shrinkage).
Possible models for the RUV are shown in Figure 3 (Equations
1-4) where ε’s are independent and normally distributed, with
a mean of zero and variance of σ2. The combined
additive-proportional error model (Figure 3, Equation 4) is most
commonly used in PK modeling.
From a population of participants, an estimate of the typical
value of the relevant PK parameters can be obtained. A new
parameter, η, can then be used to describe how an individual’s
parameter deviates from the typical value (ie, the BSV, Figure
3, Equation 5).
The BSV (η) of PK parameters will be estimated using the
relationship shown in Equation 8 (Figure 3) where θij is PK
parameter i for the jthindividual, TV(θi) is the population mean
value of the parameter, ηij is the subject-specific deviation from
the population mean of PK parameter i for individual j. The η
’s are normally distributed, with a mean of zero and a
variance-covariance matrix, ω2. The functional form chosen for
the BSV is based on the assumption that PK parameters are
log-normally distributed. In the event that this model does not
provide a good fit, other functional forms may be explored.
Initially, BSV will be included on all PK parameters, and the
necessity of all these terms will be investigated both graphically
and using formal hypothesis tests. Once the significant random
effects have been identified, the structure of the
variance-covariance matrix (ω2) can be explored. All prior model
development assumes a diagonal variance-covariance matrix
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(ie, no correlation between random effects). Comparing models
with diagonal and unstructured variance-covariance matrices
will test for the correlation between random effects.
Figure 2. Illustration of the various components of the base model for a one-compartment model with exponential between subject variability and
proportional residual unexplained variability.
Figure 3. Equations for defining different aspects of the population pharmacokinetic models including residual unexplained error (1-4), between subject
variability (5-6), and covariates (7-10).
Covariate Model Building
In order to minimize the unexplained portion of the BSV,
covariates will be added to the model. Potential covariate
relationships will first be explored by examining plots of the
included η ’s against each covariate. From these plots, the
covariates that are most likely to be significant can be identified,
and then tested formally in the model. Various functional forms
describing the relationship between the covariates and the PK
parameters are possible. Examples of commonly used functional
forms are shown in equations 7-10 of Figure 3 where Varj is
the covariate value for individual j and θVar describes the
magnitude and direction of the correlation between the covariate
and parameter. Often, covariates such as weight and age will
be centered or scaled by the mean or median; this assists in the
interpretation of the estimates and helps to stabilize the
estimation procedure. Covariates will be added to the model in
a stepwise manner by considering formal hypothesis test results,
precision of the parameter estimates and graphical techniques.
All model-building datasets include age and weight as
parameters, but data for certain brands of factor concentrate
could also include height, hematocrit, von Willebrand factor
level and blood group as possible covariates. Where available,
these covariates can be tested in model development and, if
fitting the above criteria for retention, be included in the final
model. However, the choice of model would need to take into
account the fact that clinicians using WAPPS-Hemo for
individual PK estimations are required to include age and weight
when requesting PK estimates from the WAPPS-Hemo platform,
whereas inclusion of other covariates listed above is optional.
Therefore, it is possible that a covariate may significantly
influence the PK of a molecule, but may not be recorded at the
clinical site. In order to reconcile significant covariates and
available information, multiple models may be produced for a
single molecule and a process algorithm for determining which
model to use in a given situation will be incorporated into the
WAPPS-Hemo platform. The decision tree may also incorporate
different structural models for molecules that behave differently
between subjects, and the model that provides the most precise
estimates will be selected. In all cases, the clinician will receive
a single report corresponding to whichever model was chosen
for the data provided.
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Population PK Model Evaluation
The first step in model evaluation includes the use of the
diagnostic plots outlined above to ensure that all model
assumptions are being met (eg, independent and normally
distributed residual error, normally distributed random effects).
Also, metrics such as the condition number and the variance
inflation factor may be used to assess collinearity. A bootstrap
analysis will also be performed to ensure that the model is stable
and provides precise estimates for all parameters.
Next, the models will be evaluated using cross-validation
techniques with the rich data. Either the holdout method or a
k-fold cross-validation technique will be employed, depending
on the size of the dataset in question. The bias and accuracy of
the models will be assessed using the metrics of mean error and
mean squared error.
Following evaluation with rich data, the models will be validated
using sparsely sampled data to ensure that they perform
adequately with the type of data that will be provided by
clinicians using the WAPPS-Hemo platform. Validation with
sparse data presents some challenges, since the typical methods
discussed above cannot be employed. However, a number of
strategies for evaluating models using sparse data have been
reported. These include using a subset of a complete sampling
scheme to compare performance [31,32], performing Monte
Carlo simulations [32], and examining predictive distributions
of the observed concentrations [33]. Our preferred method is
the use of a subset of a complete set of samples.
Bayesian Post Hoc Model
Bayesian estimations will also be performed in NONMEM,
using the parameter estimates from the PopPK models as
informative priors for the relevant PK parameters (eg, volume
of distribution, clearance). This step will use the same model
structures and estimation methods as previously described, and
will handle the presence or absence of PREDOSE, BASELINE,
and BLQ values in the same manner as outlined above. From
the output files, the time from dose initiation to various
concentrations (eg, 0.05, 0.02 or 0.01 IU/mL) or the
concentration at different times (eg, 24, 48, and 72 h) can be
reported with the accompanying 95% credibility intervals. The
times reported to the clinician will be the times at which the
lower boundary of the 95% credibility interval for concentration
first reaches each of these three concentration thresholds (Figure
4). For concentrations at specified times, the credibility interval
would report the lower and higher concentration value estimated
at that given time.
We have opted to use the credibility interval as the most efficient
and understandable way to report the amount of “shrinkage” of
the patient data to the population model. The interval will be
larger or smaller depending upon the amount of information
that is used either from the population (ie, larger band where
most values within the population are possible for the patient)
or the individual (ie, smaller band where more rich patient data
reduces variability). The Bayesian approach used allows this
variability to vary across different segments of the curve, being
large where no or little information is provided and small where
informative points are provided.
Reporting
A comprehensive PopPK report will be assembled for each
brand-specific model that is developed, according to the Food
and Drug Administration (FDA) guidance on PopPK reporting
[34]. The recommended sections included are shown in Textbox
3. These guidelines apply to reports submitted to the FDA,
which are not directly available to the public; however, a close
approximation of the reports we will be generating for each
model for peer-review publication is provided by Rajagopalan
and Gastonguay [35].
Figure 4. Factor concentration as a function of time (symbols: patient data, black line: predicted individual pharmacokinetic profile) where time to the
lower 95% credibility interval bound for each of the 0.05 (green line), 0.02 (blue line) or 0.01 (red line) IU/mL thresholds is reported to the clinician.
Time 0 represents time of dose initiation.
JMIR Res Protoc 2016 | vol. 5 | iss. 4 | e232 | p.8http://www.researchprotocols.org/2016/4/e232/
(page number not for citation purposes)
McEneny-King et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
Textbox 3. Recommended sections included in the comprehensive population pharmacokinetics report.
• Summary
• Introduction
• Objectives, Hypotheses and Assumptions
• Materials and Methods
• Assay
• Data
• Data Analysis Methods
• Results
• Discussion
• Application of Results
• Appendix
Results
Dense PK data has been collected for more than 20 brands of
factor concentrate. Models have been developed for all but three
molecules, and we expect to receive data for one additional
molecule in early 2017. All models will undergo further
refinement and validation, and be submitted for publication in
2017. From the WAPPS-Hemo co-investigator network, we
have collected 300 PK assessments to date and expect to reach
the 500-assessment mark by early 2017.
Discussion
Risks and Barriers
The main risk associated with the use of the WAPPS-Hemo
service is the possibility that the specific patient is outside of
the covariate space used to build the models. In such cases, the
individual estimated PK parameters may be imprecise or
essentially “wrong” and could result in suboptimal treatment
decisions. In light of this, we plan to implement risk
minimization procedures. First, we provide both average
estimates as well as their associated credibility intervals. In
cases where the patient is outside of the model development
space, we expect the intervals to be large such that clinical usage
of the predictions is discouraged. Second, each forecasted PK
is reviewed individually by an expert and appropriate warnings
will be added as needed. Third, as a general policy for
WAPPS-Hemo users, we recommend that the PK prediction is
used as a tool to speed up treatment optimization. To this end,
we recommend prospective testing with sampling around
specific times that would be valuable in decreasing uncertainty.
One of the main goals of the WAPPS-Hemo program is to
eliminate barriers to the uptake of an individualized
PopPK-driven approach to hemophilia treatment. By adopting
this tool, clinicians require fewer blood samples and circumvent
the complex calculations usually needed to implement a tailored
dosing strategy. However, the current output report may be a
potential hindrance. Although the report contains times to critical
factor levels as well as concentrations at convenient time points,
these results only pertain to the dose that was administered. A
proposed clinical module will allow clinicians to input two
parameters among dose, frequency, and desired factor level to
calculate the third. This additional functionality will allow those
that treat hemophilia to evaluate the theoretical effect of
changing dose and frequency on future plasma levels in real
time without having to submit multiple profiles through the
WAPPS-Hemo platform.
Conclusions
In summary, the WAPPS-Hemo service is predicated on valid
PopPK models. This report focuses on describing the process
for model development and evaluation, which all brand-specific
models will undergo. Rich data has been, and continues to be,
the main source of data for model development. However, as
clinical sites contribute sparse data to the repository, a greater
breadth of PK data and covariates will allow for continuous
quality improvements in the models.
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BLQ: below the limit of quantification
BSV: between subject variability
CWRES: conditional weight residuals
FIX: clotting factor IX
FVIII: clotting factor FVIII
LOQ: limit of quantification
PK: pharmacokinetic
PopPK: population pharmacokinetics
WAPPS-Hemo: Web-Accessible Population Pharmacokinetic Service - Hemophilia
WSV: within subject variability
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